<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">MD-Onco</journal-id><journal-title-group><journal-title xml:lang="en">MD-Onco</journal-title><trans-title-group xml:lang="ru"><trans-title>MD-Onco</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2782-3202</issn><issn publication-format="electronic">2782-6171</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">220</article-id><article-id pub-id-type="doi">10.17650/2782-3202-2026-6-1-35-41</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>NEW APPROACHES AND SUCCESSES IN TREATMENT OF ONCOLOGICAL PATIENTS AT THE CURRENT STAGE</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>НОВЫЕ НАПРАВЛЕНИЯ И УСПЕХИ В ЛЕЧЕНИИ ОНКОЛОГИЧЕСКИХ БОЛЬНЫХ НА СОВРЕМЕННОМ ЭТАПЕ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Multidisciplinary approach to management of patients with hereditary spherocytosis. Clinical observation</article-title><trans-title-group xml:lang="ru"><trans-title>Мультидисциплинарный подход к ведению пациентов с наследственным сфероцитозом. Клиническое наблюдение</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8443-8816</contrib-id><name-alternatives><name xml:lang="en"><surname>Ryabukhina</surname><given-names>Y. E.</given-names></name><name xml:lang="ru"><surname>Рябухина</surname><given-names>Юлия Евгеньевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>gemonk.yur@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1564-424X</contrib-id><name-alternatives><name xml:lang="en"><surname>Zeynalova</surname><given-names>P. A.</given-names></name><name xml:lang="ru"><surname>Зейналова</surname><given-names>П. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Department of Oncology</p></bio><bio xml:lang="ru"><p>кафедра онкологии</p></bio><email>gemonk.yur@mail.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Clinical Hospital “Lapino” of the “Mother and Child” Group of companies</institution></aff><aff><institution xml:lang="ru">Клинический госпиталь «Лапино» группы компаний «Мать и дитя»</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО Первый Московский государственный медицинский университет им. И.М. Сеченова Минздрава России (Сеченовский Университет)</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2026-04-08" publication-format="electronic"><day>08</day><month>04</month><year>2026</year></pub-date><volume>6</volume><issue>1</issue><issue-title xml:lang="en">MD-Onco</issue-title><issue-title xml:lang="ru"/><fpage>35</fpage><lpage>41</lpage><history><date date-type="received" iso-8601-date="2026-03-29"><day>29</day><month>03</month><year>2026</year></date><date date-type="accepted" iso-8601-date="2026-03-29"><day>29</day><month>03</month><year>2026</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2026, ABV-Press</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2026, АБВ-пресс</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="en">ABV-Press</copyright-holder><copyright-holder xml:lang="ru">АБВ-пресс</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://mdonco.abvpress.ru/jour/article/view/220">https://mdonco.abvpress.ru/jour/article/view/220</self-uri><abstract xml:lang="en"><p>Hereditary spherocytosis (HS) is a hemolytic anemia developing due to genetically induced defect in the erythrocyte membrane causing change in its shape. According to the results of studies, defects in the associated membrane proteins are caused by key mutations in the SLC4A1, EPB42, SPTA1, SPTB and ANK1 genes. The same mutation in different parts of a gene can lead to different clinical manifestations, therefore the studies of correlations between genotype and phenotype are necessary. Absence of wide availability, 100 % sensitivity and specificity of the laboratory methods used, as well as familial medical history in some cases, in conjunction with non-conformance with the clinical picture can lead to errors in HS diagnosis. Therefore, multidisciplinary approach is necessary. Progress in molecular biology led to development of next-generation sequencing which can aid in identification of new gene variants, analysis of their structure and potential pathogenicity. This will allow to significantly improve diagnostics and apply personalized treatment of HS.</p> <p>The article presents results of clinical and diagnostic observation of a 45-year-old female patient whose condition due to hemolytic crisis determined the necessity of using comprehensive approach to therapy on an urgent basis in conjunction with differential diagnostic search and identification of the cause of anemia.</p></abstract><trans-abstract xml:lang="ru"><p>Наследственный сфероцитоз (НС) – гемолитическая анемия, возникающая вследствие генетически обусловленного дефекта мембраны эритроцитов, приводящего к изменению их формы. Согласно результатам исследований, к дефектам в ассоциированных мембранных белках приводят ключевые мутации в генах SLC4A1, EPB42, SPTA1, SPTB и ANK1. При одной и той же мутации разных участков гена могут наблюдаться различные клинические проявления, что обусловливает необходимость в исследованиях корреляции генотипа с фенотипом. Отсутствие широкой доступности, 100 % чувствительности и специфичности применяемых лабораторных методов, а также в ряде случаев данных семейного анамнеза в совокупности с несоответствием клинической картине могут привести к ошибкам диагностики НС. В связи с этим основополагающим является мультидисциплинарный подход. Прогресс в изучении молекулярной биологии привел к разработке методов секвенирования нового поколения, использование которых представляется перспективным для выявления новых вариантов генов, анализа их структуры и потенциальной патогенности, что позволит значительно улучшить диагностику и проводить персонифицированное лечение НС.</p> <p>Представлены результаты клинико-диагностического наблюдения пациентки 45 лет, тяжесть состояния которой в силу развития гемолитического криза определила необходимость применения комплексного подхода к терапии в кратчайшие сроки совместно с дифференциально-диагностическим поиском и установлением генеза анемии.</p></trans-abstract><kwd-group xml:lang="en"><kwd>hereditary spherocytosis</kwd><kwd>multidisciplinary approach to diagnosis and treatment</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>наследственный сфероцитоз</kwd><kwd>мультидисциплинарный подход к диагностике и лечению</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Bolton-Maggs P.H.B., Langer J.C., Iolascon A. et al. Guidelines for the diagnosis and management of hereditary spherocytosis – 2011 update. Br J Haematol 2012;156(1):37–49. DOI: 10.1111/j.1365-2141.2011.08921.x</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Delaunay J. Molecular basis of red cell membrane disorders. Acta Haematol 2002;108(4):210–8. DOI: 10.1159/000065657</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>He M., Lv Y.C., Wei Y.H. et al. Complex heterozygous mutations in hereditary spherocytosis: a case report. World J Clin Cases 2024;12(18):3582–8. DOI: 10.12998/wjcc.v12.i18.3582</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Li X., Zhang T., Li X. et al. Identification of a novel SPTB gene splicing mutation in hereditary spherocytosis: a case report and diagnostic insights. Front Genet 2025;15:1522204. DOI: 10.3389/fgene.2024.1522204</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Xue J., He Q., Xie X. et al. Clinical utility of targeted gene enrichment and sequencing technique in the diagnosis of adult hereditary spherocytosis. Ann Transl Med 2019;7(20):527. DOI: 10.21037/atm.2019.09.163</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Van Vuren A., van der Zwaag B., Huisjes R. et al. The complexity of genotype phenotype correlations in hereditary spherocytosis: a cohort of 95 patients: genotype-phenotype correlation in hereditary spherocytosis. Hemasphere 2019;3(4):e276. DOI: 10.1097/HS9.0000000000000276</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Tole S., Dhir P., Pugi J. et al. Genotype-phenotype correlation in children with hereditary spherocytosis. Br J Haematol 2020;191(3):486–96. DOI: 10.1111/bjh.16750</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Ramjist J.K., Dubljevic T., Lapidus-Krol E. et al. Correlation of genetic mutation with outcomes in children with hereditary spherocytosis undergoing partial splenectomy: a multicentre study. J Pediatr Surg 2025;60(4):162229. DOI: 10.1016/j.jpedsurg.2025.162229</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Qin L., Jia Y., Wang H. et al. Identification of novel variants in hereditary spherocytosis patients by whole-exome sequencing. Clin Chim Acta 2025;565:119989. DOI: 10.1016/j.cca.2024.119989</mixed-citation></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">Kuzminova J.A., Plyasunova S.A., Jogov V.V., Smetanina N.S. The cytometric technique of binding of eosin-5-maleimide in diagnostic of inherent spherocytosis. Klinicheskaya i laboratornaya diagnostika = Russian Clinical Laboratory Diagnostics 2016;61(3):168–72. (In Russ.). DOI: 10.18821/0869-2084-2016-61-3-168-172</mixed-citation><mixed-citation xml:lang="ru">Кузьминова Ж.А., Плясунова С.А., Жогов В.В., Сметанина Н.С. Цитометрический метод связывания эозин-5-малеимида в диагностике наследственного сфероцитоза. Клиническая лабораторная диагностика 2016;61(3):168–72. DOI: 10.18821/0869-2084-2016-61-3-168-172</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">Hereditary spherocytosis. Clinical guidelines. 2025. Available at: https://diseases.medelement.com/disease/наследственный-сфероцитоз-кп-рф-2025/18987 (In Russ.)</mixed-citation><mixed-citation xml:lang="ru">Наследственный сфероцитоз. Клинические рекомендации. 2025. Доступно по: https://diseases.medelement.com/disease/наследственный-сфероцитоз-кп-рф-2025/18987</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">Vasilchenkova P.I., Galtseva I.V., Lukina E.A. autoimmune hemolytic anemia: the current state of the issue. Onkogematologiya = Oncohematology 2023;18(2):60–7. (In Russ.). DOI: 10.17650/1818-8346-2023-18-2-60-67</mixed-citation><mixed-citation xml:lang="ru">Васильченкова П.И., Гальцева И.В., Лукина Е.А. Аутоиммунная гемолитическая анемия: современное состояние вопроса. Онкогематология 2023;18(2):60–7. DOI: 10.17650/1818-8346-2023-18-2-60-67</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><mixed-citation>Berentsen S., Sundic T. Red blood cell destruction in autoimmune hemolytic anemia: role of complement and potential new targets for therapy. Bio Med Res Int 2015;2015:363278. DOI: 10.1155/2015/363278</mixed-citation></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">Kuzminova Z.A., Smetanina N.S. Autoimmune haemolytic anaemia: modern diagnosis and therapy. Voprosy gematologii/onkologii i imunopatologii v pediatrii = Pediatric Hematology/Oncology and Immunopathology 2016;15(3):5–11. (In Russ.). doi: 10.24287/1726-1708-2016-15-3-5-11</mixed-citation><mixed-citation xml:lang="ru">Кузьминова Ж.А., Сметанина Н.С. Аутоиммунная гемолитическая анемия: современная диагностика и терапия. Вопросы гематологии/онкологии и иммунопатологии в педиатрии 2016;15(3):5–11. DOI: 10.20953/1726-1708-2016-3-5-11</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">Feoktistova E.P., Naumova I.N., Tsvetaeva N.V. et al. Differential diagnosis of hemolytic anemias with spherocytosis. Gematologiya i transfusiologiya = Russian Journal of Hematology and Transfusiology 2020;65(1):232. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Феоктистова Е.П., Наумова И.Н., Цветаева Н.В. и др. Дифференциальная диагностика гемолитических анемий, протекающих со сфероцитозом. Гематология и трансфузиология 2020;65(1):232.</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">Savchenko V.G., Lukina E.A., Mikhaylova E.A. et al. Clinical guidelines for the management of patients with paroxysmal nocturnal hemoglobinuria. Gematologiya i transfuziologiya = Russian Journal of Hematology and Transfusiology 2022;67(3):426–39. (In Russ.). doi: 10.35754/0234-5730-2022-67-3-426-439</mixed-citation><mixed-citation xml:lang="ru">Савченко В.Г., Лукина Е.А., Михайлова Е.А. и др. Клинические рекомендации по ведению больных с пароксизмальной ночной гемоглобинурией. Гематология и трансфузиология 2022;67(3):426–39. DOI: 10.35754/0234-5730-2022-67-3-426-439</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><mixed-citation>Zenella A., Barcellini W. Treatment of autoimmune hemolytic anemias. Haematologica 2014;99(10):1547–54. DOI: 10.3324/haematol.2014.114561</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Lechner L., Jäger U. How I treat autoimmune hemolytic anemias in adults. Blood 2010;116(11):1831–8. DOI: 10.1182/blood-2010-03-259325</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Salama A., Berghofer H., Mueller-Eckhardt C. Red blood cell transfusion in warm-type autoimmune haemolytic anaemia. Lancet 1992;340(8834–8835):1515–7. DOI: 10.1016/0140-6736(92)92766-9</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Koury M.J., Ponka P. New insights into erythropoiesis: the roles of folate, vitamin B12, and iron. Annu Rev Nutr 2004;24:105–31. DOI: 10.1146/annurev.nutr.24.012003.132306</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Choi H.S., Choi Q., Kim J.A. et al. Molecular diagnosis of hereditary spherocytosis by multi-gene target sequencing in Korea: matching with osmotic fragility test and presence of spherocyte. Orphanet J Rare Dis 2019;14(1):114. DOI: 10.1186/s13023-019-1070-0</mixed-citation></ref></ref-list></back></article>
